Pharmaceutical composition containing sodium hyaluronate and chondroitin sulfate

Abstract

The invention provides a pharmaceutical composition containing sodium hyaluronate with the relatively medium molecular weight and chondroitin sulfate with the relatively low molecular weight. The molecular weight of sodium hyaluronate is 200 kD-1,000 kD, the concentration of sodium hyaluronate is 1%-2%, the molecular weight of chondroitin sulfate is 5 kD-10 kD, and the concentration of chondroitin sulfate is 1.5%-3%. The pharmaceutical composition contains chondroitin sulfate with the relatively low molecular weight, has the better treatment effect than single sodium hyaluronate and can be used for treating refractory nonbacterial cystitis, Chronic recurrent bacterial cystitis, radiation-induced cystitis, interstitial cystitis (the chronic bladder pain syndrome) and neurogenic bladder urinary system infection.

Description

technical field [0001] The invention relates to a pharmaceutical composition as a temporary substitute of GAG layer, which is used for treating chronic recurrent bacterial cystitis, radiation cystitis, interstitial cystitis (chronic bladder pain), and chemical cystitis induced by chemotherapy , neurogenic bladder urinary tract infection. Background technique [0002] Chronic recurrent bacterial cystitis is a common urinary tract infection disease, accounting for 50% to 70% of the total number of urinary tract infections, often caused by bacterial infection. Gram-negative bacilli are the most common pathogenic bacteria in non-specific infections, accounting for more than 70%. These bacteria include Escherichia coli, Proteus, Bacillus aerogenes, paraEscherichia coli, Pseudomonas aeruginosa, etc. Followed by Gram-positive cocci, common staphylococcus, streptococcus, fungal infection is less common. The main clinical symptoms are frequent urination, urgency, and pain during u...

AI Technical Summary

Problems solved by technology

[0009] Dimethyl sulfoxide can be infused into the bladder 1-2 times a week, and the symptoms begin to relieve after 3-4 weeks of treatment, which lasts for 6-8 weeks, but the effective rate is low, 50-70%

[0010] Since 1994, sodium hyaluronate has been used in the bladder perfusion treatment of interstitial cystitis. Sodium hyaluronate is the main component of the GAG ​​layer of the bladder. It plays a role in repairing the damaged GAG layer and restoring the protective barrier of the bladder mucosa. It plays an important role, but the application of sodium hyaluronate alone has the disadvantages of slow repair speed, long course of treatment and high cost

Images